BNP Paribas Financial Markets Has $16.10 Million Holdings in Viridian Therapeutics, Inc. $VRDN

BNP Paribas Financial Markets grew its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 113.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 517,398 shares of the company’s stock after buying an additional 275,091 shares during the quarter. BNP Paribas Financial Markets’ holdings in Viridian Therapeutics were worth $16,101,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd acquired a new position in shares of Viridian Therapeutics in the fourth quarter valued at approximately $36,000. Aster Capital Management DIFC Ltd acquired a new position in Viridian Therapeutics during the third quarter worth $35,000. Bessemer Group Inc. boosted its holdings in Viridian Therapeutics by 947.7% during the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock worth $45,000 after purchasing an additional 1,886 shares during the last quarter. Larson Financial Group LLC acquired a new position in Viridian Therapeutics during the third quarter worth $52,000. Finally, US Bancorp DE boosted its holdings in Viridian Therapeutics by 23.2% during the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after purchasing an additional 463 shares during the last quarter.

Analyst Ratings Changes

Several research analysts recently commented on VRDN shares. Truist Financial reduced their target price on shares of Viridian Therapeutics from $36.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, April 21st. Royal Bank Of Canada increased their target price on shares of Viridian Therapeutics from $30.00 to $34.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Evercore set a $26.00 target price on shares of Viridian Therapeutics in a report on Friday, May 15th. The Goldman Sachs Group dropped their price target on shares of Viridian Therapeutics from $36.00 to $31.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Finally, Wells Fargo & Company dropped their price target on shares of Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 31st. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $36.14.

Insider Activity

In other news, Director Fairmount Funds Management Llc purchased 1,176,470 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $19,999,990.00. Following the transaction, the director owned 5,090,928 shares of the company’s stock, valued at approximately $86,545,776. This trade represents a 30.05% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 2.40% of the company’s stock.

Viridian Therapeutics Trading Down 4.8%

VRDN stock opened at $15.78 on Friday. The company has a market capitalization of $1.63 billion, a PE ratio of -4.75 and a beta of 0.90. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.15 and a current ratio of 15.15. Viridian Therapeutics, Inc. has a 52 week low of $13.18 and a 52 week high of $34.29. The company’s 50-day simple moving average is $16.61 and its 200 day simple moving average is $25.75.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.16. The business had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.04 million. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. The firm’s quarterly revenue was up 95.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.87) EPS. As a group, sell-side analysts anticipate that Viridian Therapeutics, Inc. will post -3.87 earnings per share for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.